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Abstract: A failure to undergo apoptosis is widely thought to be an important event in cancer formation and
progression. Although there have been many studies in vitro that provide evidence for this suggestion, the roles
of apoptosis-associated proteins in cancer tissues in vivo are not as yet fully understood. Moreover, multiple
marker analyses of apoptosis-associated protein expression in non-small cell lung cancer (NSCLC) tissues are
scarce. In the present study, we investigate the expression of a group of apoptosis-associated proteins including
bcl-2, caspase-3, fas, fas ligand (fasL) and survivin, and its clinical significance in NSCLC tissues using immuno-
histochemistry (IHC). Bcl-2 staining in cancer tissue cells was found in cytoplasm and the positive rate was
38.2% (29/76). Caspase-3 staining was mainly seen in cytoplasm of cancer tissue cells (53.9% [41/76]) with a few
cases of nuclear staining (6.6% [5/76]). Fas staining was seen in cytomembrane (15.8% [12/76]) and cytoplasm
(42.1% [32/76]) of cancer tissue cells. Likewise, fasL also showed staining in cytoplasm (55.3% [42/76]) and
cytomembrane (44.7% [34/76]) of cancer tissue cells. Survivin staining was seen in cytoplasm but not nuclear of
cancer tissue cells and the positive rate was 48.7% (37/76). Higher cytoplasm expression of bcl-2 was associated
with large tumor size (≥ 3cm) in NSCLC (p < 0.05). Decreased cytoplasm expression of fas was associated with
poor grade in NSCLC (p < 0.05). A negative correlation was found between bcl-2 and cytoplasm caspase-3
expression in NSCLC (p < 0.001). No separate expression of the apoptosis-associated proteins in NSCLC was
linked to overall survival of patients (p > 0.05). Multiple marker analyses revealed caspase-3+/cytomembrane
fasL– to be linked to better survival of patients with NSCLC (p < 0.05). These results indicate that apoptosis-
-associated proteins may impact a variety of clinicopathological features of NSCLC and may co-operatively influ-
ence the prognosis of patients with this malignant tumor. (Folia Histochemica et Cytobiologica 2011, Vol. 49,
No. 2, 231–239)
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Introduction
Dysregulation of apoptosis plays an important role
in the development of a variety of human patholo-
gies, including cancer [1–5]. Apoptosis-associated
proteins are studied in vitro to find out their abnor-
mality and the consequent impacts on cancer cells.
Studies have shown that cancer cells invariably have
abnormalities in one or more apoptotic pathways,
determining a survival advantage of these cells over
their normal counterparts [1, 2, 6–9]. Furthermore,
abnormalities in the apoptotic response also play
a role in the development of drug resistance by cancer
cells [1, 4, 6, 10–14]. There is growing interest in the
development of therapeutic strategies that kill can-
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cer cells via activation of the apoptotic pathways. But
in fact, there are more complicated contexts of can-
cer cells in cancer tissues compared to cell lines in
vitro. The clinical significance of separate apoptotic
regulatory proteins’ expression in lung cancer has
been widely described. But there is little data of
multiple marker analysis concerning immunoreac-
tivity of apoptosis-associated proteins regarding dif-
ferent pathways of apoptosis in relation to clinico-
pathological parameters and patients’ prognosis.
Here, we present a study investigating the expres-
sion of a group of apoptosis-associated proteins in
non-small cell lung cancer (NSCLC) tissues, and
its clinical significance.
Material and methods
Tissue samples. Formalin-fixed, paraffin-embedded
blocks of NSCLC tissues (76 cases, from 1998 to 2005)
were randomly drawn from the Department of Patholo-
gy of the First Affiliated Hospital of China Medical Uni-
versity, Shenyang, China, after approval by the Institu-
tional Review Board. All the cases had complete follow-
-up records. Informed consent was obtained from all en-
rolled patients prior to surgery. None of the patients had
received chemotherapy or radiotherapy before tumor
excision. Of the patients, 46 were male and 30 were fe-
male, a 1.53:1 ratio of male to female. Patients’ ages at
the time of surgery ranged from 26 to 78 years, average
57.1. The tumors were classified according to the TNM
stage revised by the International Union Against Cancer
(UICC) in 2002 [15] and consisted of 38 (50.0%) stage I,
12 (15.8%) stage II, 25 (32.9%) stage III and one (1.3%)
stage IV tumors. Histological tumor subtypes were as-
sessed according to the criteria for classification of lung
cancer by the World Health Organization (WHO) [16]
by at least two pathologists. There were 34 (44.7%) squa-
mous cell carcinomas (SCCs), 39 (51.3%) adenocarcino-
mas, two (2.6%) large cell carcinomas, and one (1.3%)
adenosquamous carcinoma.
Immunohistochemical staining. Immunohistochemistry
(IHC) assay for bcl-2, caspase-3, fas, fas ligand (fasL) and
survivin expression was performed on the sequential par-
affin-embedded tissue sections using the peroxidase la-
beled streptavidin-biotin method. Commercially available
antibodies for bcl-2 (MS-597), caspase-3 (MS-1121), sur-
vivin (RB-1629) (Thermo Fisher Lab Vision, Fremont, CA,
USA, dilution: bcl-2: 1:50; caspase-3: 1:50; survivin: 1:100),
fas (SC-715) and fasL (SC-834) (Santa Cruz Technology,
Santa Cruz, CA, USA, dilution: fas: 1:100, fasL :1:100) were
used to recognize these proteins. Immunohistochemical
staining was performed using UltraSensitive™ S-P kits
(Maixin Biotechnology, Fuzhou, Fujian, China) according
to the manufacturer’s instructions. Sequential slides with
4 μm-thick tissue sections were deparaffinized and hydrat-
ed in sequential treatment of xylene, ethanol and water.
Citrate buffer (0.01 M citric acid, pH 6.0) was used to re-
trieve antigens in a heated pressure cooker. Endogenous
peroxidase activity and non-specific binding were blocked
with 3% H2O2 and non-immune sera, respectively. Sections
were then incubated with primary antibodies overnight at
4°C. The following day, biotinylated secondary antibody
and streptavidin-horseradish peroxidase (Maixin Biotech-
nology) were added. The peroxidase reaction was devel-
oped with 3,3’-diaminobenzidine tetrahydrochloride
(Maixin Biotechnology). Counterstaining was done light-
ly with hematoxylin, and the sections were dehydrated in
alcohol before mounting. For the negative control, phos-
phate-buffered saline (PBS) was used in place of the pri-
mary antibodies. The positive control was as follows: bcl-2:
lymph tissues of tonsil; caspase-3: appendix mucosa; fas:
hepatocarcinoma; fasL: liver epithelium; survivin: stom-
ach mucosa epithelium.
Immunohistochemical evaluation. The expression pat-
tern of the proteins was evaluated by at least two investi-
gators who did not know the antibodies used and had no
knowledge of the patients’ clinical status. Cases with dis-
crepancies were jointly re-evaluated by the investigators,
and a consensus was obtained. Scoring of immunohis-
tochemistry was based on two parameters: the propor-
tion of immunopositive cells and their intensity of immu-
noreactivity. The proportion of immunopositive cells was
categorized as follows: 0: < 10%; 1: ≥ 10% to < 25%;
2: ≥ 25% to < 50%; 3: ≥ 50% to < 75% and 4: ≥ 75%.
The staining intensity was categorized by relative inten-
sity as follows: 0: no positivity; 1: weak; 2: moderate and
3: strong. A final immunoreactivity score of each sample
was obtained by multiplying the two individual scores. To
obtain final statistical results, a final score of less than 2
was considered to be negative (also represented by ‘–’),
while scores of 2 or more were considered to be positive
(also represented by ‘+’).
Statistical analysis. All statistical analyses were per-
formed using SPSS 13.0 for Windows (SPSS Inc., Chi-
cago, IL, USA). The Chi-Square test was used to ana-
lyze the relationship between expression of apoptosis-
associated proteins and clinicopathological factors.
Spearman’s correlation coefficient (r) was used to find
the correlation between expressions of the proteins. The
probabilities of overall survival were calculated using
the Kaplan–Meier method and were compared using the
log-rank test. For determining factors related to overall
survival, a Cox proportional hazard model was utilized
and p values of less than 0.05 were considered statisti-
cally significant.
233Apoptosis-associated proteins in non-small cell lung cancer
©Polish Society for Histochemistry and Cytochemistry




Expression of five apoptosis-associated
proteins in NSCLC tissues
Staining of five apoptosis-associated proteins in
NSCLC tissues was shown in Figure 1. Generally,
weak bcl-2 staining in cancer tissue cells was found in
cytoplasm. The positive rate of bcl-2 expression in
NSCLC was 38.2% (29/76). Caspase-3 staining was
mainly seen in cytoplasm of cancer tissue cells (53.9%
[41/76]). A few cases of nuclear staining were also
found (6.6% [5/76]), while there was only one case
with sole nuclear staining. Fas staining was seen in
cytomembrane (15.8% [12/76]) and cytoplasm (42.1%
[32/76]) of cancer cells with a total positive rate of
48.7% (37/76). Its staining is generally very weak in
NSCLC with a mean staining score of 2.16 in membrane
and 2.69 in cytoplasm fas positive cases. FasL showed
staining in cytoplasm (55.3% [42/76]) and cytomembrane
(44.7% [34/76]) of NSCLC tissue cells with a total pos-
itive rate of 63.2% (48/76). Survivin staining was seen in
cytoplasm but not nuclear of NSCLC tissue cells and
the positive rate was 48.7% (37/76).
Relationship between expression of apopto-
sis-associated proteins and clinicopathologi-
cal factors in NSCLC
The relationship between expression of five apopto-
sis-associated proteins and different clinicopatholog-
ical factors in NSCLC is shown in Table 1. No signif-
icant correlation was found between the expression
of caspase-3, fasL or survivin in NSCLC and any of
the clinicopathological factors (p > 0.05). Higher cy-
toplasm expression of bcl-2 was associated with large
tumor size (≥ 3 cm) in NSCLC (p < 0.05). Decreased
cytoplasm expression of fas was associated with poor
grade in NSCLC (p < 0.05). There was a tendency
for an association between membrane fasL expres-
sion and advanced TNM stages in NSCLC for a close
p value (p = 0.082).
Relationship between expression of five
apoptosis-associated proteins in NSCLC
The relationship between expression of five apopto-
sis-associated proteins in NSCLC is shown in Table
2. A negative correlation was found between bcl-2 and
cytoplasm caspase-3 expression (p < 0.001) (Table 2,
Figure 2). There was no correlation between expres-
sion of other proteins (p > 0.05). To make further
multiple marker analyses for patients’ survival, the
76 cases were divided into 40 groups each combining
two protein expressions, such as bcl-2+/caspase-3+,
bcl-2+/caspase-3–, and so on. The groups and the cas-
es are shown in Table 2. As the number of the cohort
was limited, we didn’t divide the tumors into further
groups containing three or more markers.
Kaplan–Meier analysis
The median follow-up period of patients with NSCLC
was 45.6 months, with a range from three to 111
months. The overall mean survival time was 46.11 ±
± 3.39 months. The overall Kaplan–Meier survival
curves for expression of five apoptosis-associated pro-
teins revealed no separate expression of the five apo-
ptosis-associated proteins in NSCLC to be linked to
overall survival (p > 0.05). We also analyzed the prog-
nostic significance of separate expression of these
proteins in NSCLC with advanced TNM stages
(III and IV stages), but no significant result was obtained
(p < 0.05). To further evaluate prognostic factors for
patients with NSCLC, a multivariate Cox regression
analysis was carried out. As shown in Table 3, in an
analysis of 76 patients, lymph node metastasis, tumor
size and TNM stage were independent factors that
impacted lung cancer patients’ prognosis (p < 0.05).
But sex, age, histological type, differentiation and sep-
arate expression of the five proteins had no statistical
correlation to prognosis (p > 0.05). The log-rank test
for multiple marker analyses for patients’ survival re-
vealed a difference in the survival time of patients based
on the presence or absence of caspase-3 and cytomem-
brane fasL expression. The survival time of patients
with caspase-3+/cytomembrane fasL– tumors (60.81 ±
± 4.92 months) was significantly longer than the other
three groups (p < 0.001) (Figure 3). Patients with
caspase-3–/cytomembrane fasL+ tumors showed short-
er survival time (29.49 ± 4.37 months) than caspase-3–/
/cytomembrane fasL– tumors (42.07 ± 3.88 months)
(p < 0.05). No significant difference was found between
the caspase-3+/cytomembrane fasL+ group (33.70 ±
± 5.25 months) and the above two groups (p > 0.05).
No significant difference was found in patients’ prog-
nosis based on expressions of other proteins (p > 0.05).
Discussion
Apoptosis, the commonest and best-defined form of
programmed cell death, is a physiological process of
cell elimination, which is important for the mainte-
nance of embryonic development and cell homeosta-
sis [17–20]. It is generally agreed that cell populations
are tightly regulated by their rates of proliferation,
differentiation and death. Dysfunction of any one of
these processes can result in either uncontrolled cell
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Figure 1. Expression of apoptosis-associated proteins in NSCLC tissues using IHC. Bcl-2 staining in cytoplasm in SCC
(A) and adenocarcinoma (B). Lymphocytes were also stained in nuclear as an intrinsic control in caspase-3 expression in
cytoplasm and nuclears in SCC (C) and adenocarcinoma (D). Weak and diffuse cytoplasm and weak cytomembrane
staining of fas in SCC (E) and adenocarcinoma (F). Cytoplasm and membrane staining of fasL in SCC (G) and adenocar-
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Table 1. Relationship between expression of apoptosis-associated proteins and clinicopathological factors in non-small
cell lung cancer (total cases = 76)
Variables          All bcl-2 caspase 3 fas fasL survivin
cases
– + – + – + – + – +
Gender
Male  46 28 18 23 23 28 18 27 19 21 25
Female  30 19 11 12 18 16 14 15 15 18 12
Age (years)
 £ 55  31 19 12 16 15 19 12 17 14 17 14
> 55  45 28 17 19 26 25 20 25 20 22 23
Histological type
Squamous cell
Carcinoma  34 22 12 18 16 21 13 19 15 14 20
Adenocarcinoma  39 23 16 17 22 21 18 21 18 24 15
Large cell carcinoma  2 1 1 0 2 1 1 1 1 0 2
Adenosquamous
Carcinoma  1 1 0 0 1 1 0 1 0 1 0
Grade
Well  20 13 7 10 10 11 12 13 7 10 10
Moderate  21 13 8 11 10 9 11 12 9 11 10
Poor  35 21 14 14 21 24 9# 17 18 18 17
TNM stage
 I and II  50 34 16 24 26 29 21 31 19 23 24
III and IV  26 13 13 11 15 15 11 11 15 13 13
Tumor size
< 3 cm 32 24 8 15 17 20 12 18 14 13 19
≥ 3cm  44 23 21* 20 24 24 20 24 20 26 18
Lymph node metastasis
Yes 48 31 17 21 27 26 22 25 23 26 22
No 28 16 12 14 14 18 10 17 11 13 15
The Chi-Square test was used; bcl-2, caspase-3, fas and survivin: cytoplasm staining; fasL: cytomembrane staining; *p < 0.05; #p < 0.05,
poor vs. well and moderate grades; all other p values > 0.05
Table 2. Correlation between expression of five apoptosis-associated proteins and cases of 40 tumor groups based on
expression of two associated proteins in non-small cell lung cancer (total cases = 76)
bcl-2+ bcl-2– caspase 3+ caspase 3– fas+ fas– fasL+ fasL–
caspase-3+ 8  33 – – – – – –
caspase-3– 21  14* – – – – – –
fas+ 14  18 17  15 – – – –
fas– 15  29 24  20 – – – –
fasL+ 12  22 15  19  13  21 – –
fasL– 17  25 26  16  19  23 – –
survivin+ 11  26 19  18  15  22   14   23
survivin– 18  21 22  17  17  22   20   19
p and r (correlation coefficient) values were obtained by Spearman correlation test. bcl-2, caspase-3, fas and survivin: cytoplasm staining; fasL:
cytomembrane staining; *p < 0.001; r = –0.415
growth or uncontrolled cell death [1–5, 21–23]. But it
remains unclear as to what degree cell proliferation
and/or cell death must occur to initiate tumor forma-
tion. The analysis of apoptosis-associated proteins is
important because of the key role those processes play
in carcinogenesis.
We investigated five apoptosis-associated proteins
in NSCLC tissues, namely bcl-2, caspase-3, fas, fasL,
and survivin. According to data updates, these proteins
may be important for the balance of cell proliferation
and cell death to maintain cellular homeostasis in nor-
mal lung tissues [24–28]. But their actual roles in can-
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cer tissues including NSCLC are less clear. Though
many studies have found heterogeneity of expression
of apoptosis-associated proteins in NSCLC, we don’t
yet know to what degree they influence apoptosis of
the cancer cells in NSCLC tissues. In addition, it re-
mains controversial as to how they influence the bio-
logical features of cancer cells in vivo.
In the current study, we found bcl-2, which was
originally cloned from the t(14;18) translocation
breakpoint found in follicular B-cell lymphomas, to
be related to large tumor size in NSCLC. Bcl-2 is
a prototype of the proteins involved in anti-apoptotic
regulatory pathway, and its overexpression may re-
sult in cell proliferation, as cells normally scheduled
for death may undergo further mutations [29, 30].
Overexpression of bcl-2 may be involved in stress re-
sponse against hypoxia which is frequently seen in
a solid tumor as a result of tumor expansion to prevent
cancer cells from apoptosis. Despite the bcl-2 nega-
tive influence on apoptosis, the results of published
studies indicate positive or no prognostic value of bcl-2
in lung cancer [31–35], though the reason why is un-
clear and conflicts still exist. It is possible that bcl-2
expression may be associated with other features of
tumors that define a more favorable prognosis func-
tion besides its function to promote tumor growth. In
Figure 2. Bcl-2 and caspase-3 expression in sequential sections showing a negative correlation. Weak staining (score < 2)
of bcl-2 in SCC (A) and concurrently positive staining (score > 2) in adenocarcinoma (B). Positive staining of caspase-3 in
cytoplasm (score > 2) in SCC (C) and concurrently negative staining (score = 0) in adenocarcinoma (× 400)
Table 3. Multivariate Cox proportional hazard analysis for overall survival of 76 patients with non-small cell lung cancer
Factors b SE p Exp (b) 95% CI for Exp (b)
TNM stage* 0.512 0.295 0.003 1.209 0.962–2.592
Tumor size* 0.618 0.392 0.045 2.314 1.174–2.833
Lymph node metastasis* 1.327 0.501 0.002 4.372 1.032–9.540
bcl-2 expression 0.276 0.183 0.074 2.013 1.282–4.257
caspase-3 expression 0.325 0.279 0.083 1.784 1.192–3.490
fas expression 0.309 0.326 0.102 1.934 1.097–3.052
fasL expression 0.418 0.187 0.095 1.046 0.992–2.843
survivin expression 0.653 0.254 0.189 2.308 1.347–4.016
bcl-2, caspase-3, fas and survivin: cytoplasm staining; fasL: cytomembrane staining; *independent factors (p < 0.05)
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our study, we did not find bcl-2 expression in NSCLC
to be associated with patients’ survival. However,  we
can’t deny its possible functions in this malignant tu-
mor, because the study was limited in that the cohort
we studied was limited and no post-surgical treatment
information was available for the patients included
in the database, which may have contributed to dif-
ferences in survival.
Caspase-3 is an important downstream effector
cysteine protease in the apoptotic pathway. Either
a positive or a negative correlation between expression
of caspase-3 and malignancy of the tumor has been
reported [36, 37]. Our study did not find it was asso-
ciated with any of the clinicopathological factors in
NSCLC. As the antibody we used can recognize both
pro- and activated caspase-3, the activity of caspase-
3 in NSCLC tissues was not clear. It may be neces-
sary that this activity is taken into account to further
understand its influence on the biology of NSCLC.
But, as we will discuss later, despite this, the expres-
sion of caspase-3 does have an influence on patients’
survival, though not separately.
Apoptosis pathway through fas and its ligand fasL
is involved in tissue homeostasis and the elimination
of target cells by cytotoxic T cells. Loss of fas or the
function of fas has been implicated in tumor progres-
sion of several cancers [38, 39]. Decreased cell sur-
face fas expression in lung tumors has also been ob-
served in some studies [40–42]. Consistent with these
studies, we also found a very low level of membrane
fas in NSCLC, although the positive rate of cytoplasm
fas expression in our study was relatively higher than
those studies. This may be due to the different as-
sessment methods used. But scores of fas expression
in cytoplasm in NSCLC in our study were generally
very small, ranging from 0 to 6, with a median of 2.69.
Our study didn’t find fas membrane expression to be
associated with any pathological features of NSCLC
and patients’ outcome. We cannot rule out its possi-
ble role in NSCLC, because the small number of pos-
itive cases made it difficult to reach a conclusion.
A cohort including more cases would seem to be im-
portant for analysis of this protein. In addition, the
distinct pattern of fas expression in tumor stroma
should also be taken into account to further investi-
gate its function in NSCLC, which is absent from our
study. Interestingly, we found that decreased cyto-
plasm expression of fas was associated with poor grade
in NSCLC, which was not mentioned in other stud-
ies. But the reason for this was not made clear in our
study. It seems that in better-differentiated tumors,
abnormal cellular localization of fas is more frequent,
while in poorly-differentiated tumors, fas expression
was entirely reduced. On the other hand, membrane
fasL expression was found to be increased in many
studies [41, 43] and likewise in our study. Increased
fasL expression is considered to participate in tumor
development and immune escape [38, 40]. We did not
find fasL alone to have any association with clinico-
pathological factors and patients’ survival, but it is
possible that fasL may have an impact on the clinical
stage of NSCLC. In addition, fasL in conjunction with
caspase-3 may have an influence on the outcome of
patients with NSCLC.
Survivin is a member of the family of inhibitors of
apoptosis proteins. It functions as a key regulator of
programmed cell death. The prognostic value of sur-
vivin for survival of patients with NSCLC remains
controversial. In some reports, survivin-positive ex-
pression correlated with more aggressive behavior and
poorer prognosis [44, 45]. Recent studies found nu-
clear survivin to be more important compared to cy-
toplasm suvivin as a promising prognostic marker
[46, 47]. In our study did not find any association between
survivin expression and clinicopathological factors and
patients’ survival. As the antibody we used in our study
can recognize only cytoplasm survivin, as the manu-
facturer’s instructions state, we cannot deny the pos-
sible role of nuclear survivin in NSCLC. But our study
does not support the prognostic significance of cyto-
plasm survivin in NSCLC.
The proteins studied here respectively play roles
in the two fundamental pathways in apoptosis: the
death receptor pathway and the mitochondrial path-
way. In in vitro studies, these proteins are proved to
be concurrently involved in cell apoptosis and have
interactions with each other. But in our study, we only
found bcl-2 and caspase-3 to have correlation in
NSCLC tissues. It seems that the apoptosis pathways
in cancer tissues are more complicated than that in
Figure 3. Comparison of patients’ survival according to
combined caspase-3 and cytomembrane fasL expression in
non-small cell lung cancer: survival time of patients with
caspase-3+/cytomembrane fasL– tumors was significantly
longer than the other three groups (p < 0.001)
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non-tumor or tumor in vitro cell lines. The negative
correlation between bcl-2 and caspase-3 in our study
is not simple to explain for a complicated context in
cancer tissues. But this finding seems to be consis-
tent with the suggestion that bcl-2 may regulate cell
death by controlling mitochondrial membrane per-
meability and inhibiting caspase activity. We can in-
fer from this result that the apoptosis-associated pro-
teins may actually directly or indirectly interact with
each other, but perhaps in different ways from those
in cell lines.
The understanding of apoptosis has provided the
basis for novel targeted therapies that can induce
death in cancer cells or sensitize them to established
cytotoxic agents and radiation therapy. However, to
date, despite the great excitement over potential ben-
efits of targeting the apoptosis pathways, the likeli-
hood of achieving long-lasting therapeutic benefits for
patients with malignant tumors, including NSCLC,
remains uncertain. Our study did not find any of the
proteins studied here to have independent signifi-
cance for patients’ prognosis. We can’t deny the pos-
sible influence of these proteins on patients’ progno-
sis, but we bear in mind the importance for any of the
proteins to be reconsidered in the context of levels of
other apoptotic or non-apoptotic proteins to show its
prognostic importance.
We found caspase-3+/cytomembrane fasL– predicts
a better survival of patients with NSCLC compared
to the other groups. Though caspase-3 is one of the
most important molecules in the apoptosis cascade,
studies of it in terms of lung cancer outcome have
been limited. Several studies of caspase-3 expression
have shown conflicting effects on survival [48–50]. Our
study indicates that the total amount of caspase-3
expression was important for its function in NSCLC
tissues, although the activity of the protein remains
unclear. In addition, our finding indicates the two
apoptosis-associated proteins may co-operatively af-
fect patients’ survival, rather than only one protein
acting alone. As for another apoptosis-associated pro-
tein we studied, bcl-2, some studies suggest that the
combination of decreased bcl-2 expression and in-
creased p53 expression predicts the poorest survival
[32, 34]. There is growing interest in combining the
results of two or more markers to provide prognostic
information, although data is still scarce. It seems that
the overall status of the cell death machinery, rather
than just the expression levels of the individual pro-
teins, might explain how it affects tumorigenesis.
Combined therapies simultaneously targeting apop-
tosis and survival signaling defects might shift the
balance from tumor growth stasis to cytotoxic thera-
peutic responses that might be associated with great-
er therapeutic benefits.
In conclusion, our study indicates a marked het-
erogeneity of apoptosis-associated proteins includ-
ing bcl-2, caspase-3, fas, fas-L, and survivin in
NSCLC tissues, the possible interaction of bcl-2 and
fas with the tumor’s clinicopathological features, the
possible interaction of bcl-2 and caspase-3 with each
other, and the potential influence of caspase-3 and
fasL coexpression on patients’ prognosis. To date,
information about the function of apoptosis-associ-
ated proteins in NSCLC is still limited. More stud-
ies are needed to understand the roles of apoptosis-
associated proteins in the carcinogenesis and
progress of this malignant tumor. Further under-
standing of the molecular defects and the regula-
tion of the apoptosis pathways in tumors will help
with the discovery of novel targeted agents and the
design of clinical trials that are based on the specific
molecular defects.
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